Covidien To Exit OneShot™ Renal Denervation Program
DUBLIN, Ireland--(BUSINESS WIRE)--Covidien plc (NYSE: COV) today announced it will exit its OneShot™ Renal Denervation program. This voluntary action is primarily in response to slower than expected development of the renal denervation market. The OneShot system is an over-the-wire balloon-based irrigated catheter technology for the treatment of hypertension. The system received CE Mark in February 2012 and is not approved for sale in the United States.
Help employers find you! Check out all the jobs and post your resume.